Cabaletta Bio 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
7 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DSG3-CAART / Cabaletta Bio
NCT04422912: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Recruiting
1
55
US
DSG3-CAART or CABA-201
Cabaletta Bio
Pemphigus Vulgaris
01/29
01/29
MuSK-CAART / Cabaletta Bio
NCT05451212: Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

Recruiting
1
24
US
MuSK-CAART
Cabaletta Bio
MuSK Myasthenia Gravis
10/28
10/28
resecabtagene autoleucel (CABA-201) / Cabaletta Bio
RESET-Myositis, NCT06154252: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Recruiting
1/2
24
Europe, US
CABA-201 following preconditioning with fludarabine and cyclophosphamide
Cabaletta Bio
Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
07/28
07/28
CAB-201-003, NCT06328777: RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Recruiting
1/2
12
US
CABA-201
Cabaletta Bio
Systemic Sclerosis, Scleroderma
07/29
07/29
RESET-MG, NCT06359041: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Recruiting
1/2
12
US
CABA-201
Cabaletta Bio
Generalized Myasthenia Gravis (gMG)
09/29
09/29
CAB-201-005, NCT07006805: RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

Not yet recruiting
1/2
12
NA
CABA-201
Cabaletta Bio
Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting, Multiple Sclerosis, Multiple Sclerosis (Relapsing Remitting), Multiple Sclerosis (MS) - Relapsing-remitting, Progressive Multiple Sclerosis
09/28
10/29
RESET-SLE, NCT06121297: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Recruiting
1/2
12
Europe, US
CABA-201
Cabaletta Bio
Systemic Lupus Erythematosus, Lupus Nephritis
12/27
12/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DSG3-CAART / Cabaletta Bio
NCT04422912: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Recruiting
1
55
US
DSG3-CAART or CABA-201
Cabaletta Bio
Pemphigus Vulgaris
01/29
01/29
MuSK-CAART / Cabaletta Bio
NCT05451212: Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

Recruiting
1
24
US
MuSK-CAART
Cabaletta Bio
MuSK Myasthenia Gravis
10/28
10/28
resecabtagene autoleucel (CABA-201) / Cabaletta Bio
RESET-Myositis, NCT06154252: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Recruiting
1/2
24
Europe, US
CABA-201 following preconditioning with fludarabine and cyclophosphamide
Cabaletta Bio
Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
07/28
07/28
CAB-201-003, NCT06328777: RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Recruiting
1/2
12
US
CABA-201
Cabaletta Bio
Systemic Sclerosis, Scleroderma
07/29
07/29
RESET-MG, NCT06359041: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Recruiting
1/2
12
US
CABA-201
Cabaletta Bio
Generalized Myasthenia Gravis (gMG)
09/29
09/29
CAB-201-005, NCT07006805: RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

Not yet recruiting
1/2
12
NA
CABA-201
Cabaletta Bio
Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting, Multiple Sclerosis, Multiple Sclerosis (Relapsing Remitting), Multiple Sclerosis (MS) - Relapsing-remitting, Progressive Multiple Sclerosis
09/28
10/29
RESET-SLE, NCT06121297: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Recruiting
1/2
12
Europe, US
CABA-201
Cabaletta Bio
Systemic Lupus Erythematosus, Lupus Nephritis
12/27
12/27

Download Options